NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
Clinical trials for NEOVASCULAR AGE-RELATED MACULAR DEGENERATION explained in plain language.
Never miss a new study
Get alerted when new NEOVASCULAR AGE-RELATED MACULAR DEGENERATION trials appear
Sign up with your email to follow new studies for NEOVASCULAR AGE-RELATED MACULAR DEGENERATION, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
One-Shot gene therapy aims to free patients from monthly eye injections
Disease control Recruiting nowThis study is testing a one-time gene therapy called RGX-314 for people with wet age-related macular degeneration (wet AMD), a leading cause of vision loss. The goal is to see if this single treatment can help the eye make its own medicine to control the disease, potentially redu…
Matched conditions: NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
Phase: PHASE2, PHASE3 • Sponsor: AbbVie • Aim: Disease control
Last updated Apr 01, 2026 22:47 UTC
-
Researchers check if eye implant harms cornea in macular degeneration patients
Disease control Recruiting nowThis study aims to see if a refillable implant that continuously delivers medication into the eye affects the health of the cornea, the eye's clear front layer. It will involve about 188 people with wet age-related macular degeneration who receive the implant. Researchers will co…
Matched conditions: NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
Phase: PHASE4 • Sponsor: Genentech, Inc. • Aim: Disease control
Last updated Apr 01, 2026 14:43 UTC
-
One-Time gene shot aims to free patients from monthly eye injections
Disease control Recruiting nowThis study is testing whether a single gene therapy injection can reduce the need for frequent eye injections in people with wet age-related macular degeneration (AMD), a leading cause of vision loss. About 561 participants aged 50+ who have been receiving regular eye injections …
Matched conditions: NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
Phase: PHASE3 • Sponsor: AbbVie • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
One-Shot gene therapy tested to replace frequent eye injections for vision loss
Disease control Recruiting nowThis early-stage study is testing a single gene therapy injection, called LX111, for people with wet age-related macular degeneration (AMD), a leading cause of vision loss. The main goal is to see if this one-time treatment is safe and if it can help control the disease, potentia…
Matched conditions: NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
Phase: EARLY_PHASE1 • Sponsor: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
One shot for sight? trial tests single injection to treat common cause of blindness
Disease control Recruiting nowThis study is testing a single injection into the eye (called SAR402663) for people with wet age-related macular degeneration (AMD), a leading cause of vision loss. The main goal is to see if this one-time treatment is safe and if it can help control the disease, potentially redu…
Matched conditions: NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
Phase: PHASE1, PHASE2 • Sponsor: Sanofi • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC
-
Eye implant could replace monthly injections for blinding disease
Disease control Recruiting nowThis study is testing a small, refillable implant placed in the eye that slowly releases a medicine (ranibizumab) for six months. It is being compared to the standard treatment of receiving the same medicine as a monthly injection into the eye. The goal is to see if the implant w…
Matched conditions: NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Mar 30, 2026 14:30 UTC
-
Tiny eye implant could replace frequent injections for vision loss
Disease control Recruiting nowThis study is testing a small, refillable implant placed in the eye to deliver a steady dose of medication for wet age-related macular degeneration (AMD). The goal is to see if refilling the implant every 36 weeks can maintain vision as effectively as standard monthly or bimonthl…
Matched conditions: NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Mar 30, 2026 14:28 UTC
-
New eye injection aims to halt leading cause of blindness
Disease control Recruiting nowThis study is testing an experimental eye injection called IBI302 for people with 'wet' age-related macular degeneration, a major cause of vision loss. The main goal is to see if the treatment helps preserve vision over one year and is safe. About 800 participants will receive th…
Matched conditions: NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
Phase: PHASE2 • Sponsor: Innovent Biologics Technology Limited (Shanghai R&D Center) • Aim: Disease control
Last updated Mar 27, 2026 12:39 UTC
-
Home eye scanner could cut injections for blinding eye disease
Disease control Recruiting nowThis study is testing if using a home scanner to check the eye daily can help doctors give fewer injections while keeping vision just as good for people with wet age-related macular degeneration (AMD). It compares this new approach to the current standard treatment schedule. The …
Matched conditions: NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
Phase: PHASE3 • Sponsor: Jaeb Center for Health Research • Aim: Disease control
Last updated Mar 23, 2026 15:19 UTC
-
Tracking vision drug performance in routine chinese eye care
Disease control Recruiting nowThis study aims to understand how well the eye injection drug faricimab works and how safe it is in everyday medical practice in China. It will follow 1,000 patients with diabetic macular edema, retinal vein occlusion, or neovascular age-related macular degeneration who are alrea…
Matched conditions: NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Mar 23, 2026 15:18 UTC
-
Permanent eye implant aims to free patients from frequent injections
Disease control Recruiting nowThis study is checking the long-term safety of a small, permanent implant placed in the eye that slowly releases medication for wet age-related macular degeneration (AMD). It is for people who have already been in related studies testing this device. The main goal is to see if th…
Matched conditions: NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Mar 19, 2026 14:56 UTC
-
Tracking eye injections in real patients
Knowledge-focused Recruiting nowThis study is collecting information on how well the eye injection drug faricimab works for people with wet age-related macular degeneration or diabetic macular edema in real-world doctor's offices. It will follow 850 patients for 2 years to see how their vision changes, how ofte…
Matched conditions: NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
Sponsor: Hoffmann-La Roche • Aim: Knowledge-focused
Last updated Mar 31, 2026 12:11 UTC